Business Context and Reporting Period
Company: CalciMedica, Inc. (CALC)
Filing Type: Form 8-K (Current Report)
Date of Report: January 19, 2024
Reporting Period: As of December 31, 2023 (preliminary financial data)
Business Overview: The Company is an emerging growth company focused on developing Auxora for the treatment of acute pancreatitis (AP) and acute kidney injury (AKI).
Key Financial Metrics and Capital Structure
Liquidity Position (as of Dec 31, 2023):
- Cash, cash equivalents, and short-term investments: $11.2 million (preliminary, unaudited).
- Securities Issued: 5,113,812 shares of Common Stock and 351,352 Pre-Funded Warrants.
- Warrants Issued: Tranche A and Tranche B Common Warrants covering up to 5,465,164 shares.
- Purchase Price: $3.70 per share (or $4.3915 for directors/employees/consultants).
- Expected Gross Proceeds: $20.4 million upfront.
- Potential Additional Proceeds: Up to $34.2 million upon full exercise of warrants.
- Total Potential Capital: Approximately $55 million.
- Closing Schedule: Initial closing expected January 23, 2024; second closing expected February 5, 2024.
- The filing does not provide specific data on revenue, profit, operating margins, or existing debt obligations.
Material Changes and Agreements
Material Definitive Agreement:
- Entered into a Securities Purchase Agreement with accredited investors for a private placement.
- Entered into a Registration Rights Agreement requiring the Company to file a registration statement within 30 days and use commercially reasonable efforts to have it declared effective within 45 days (or 75 days if under full review).
- Agreed to a lock-up provision prohibiting the issuance of Common Stock or equivalents for 90 days post-closing or until the registration statement is effective, whichever is later.
- Agreed to a one-year restriction on Variable Rate Transactions.
- JonesTrading Institutional Services LLC served as the exclusive placement agent.
- Fee: Up to 5.00% of aggregate gross proceeds.
- Additional compensation: Warrants to purchase 78,349 shares of Common Stock at $0.0001 per share.
Outlook, Risks, and Management Commentary
Use of Proceeds:
- Upfront net proceeds combined with current cash are expected to fund ongoing and planned Phase 2 clinical trials for Auxora in AP and AKI.
- Aggregate net proceeds (assuming full warrant exercise) are expected to fund subsequent, potentially pivotal, clinical trials.
- Tranche A Warrants: Exercise price $5.36; expire on December 31, 2024, or 30 days after topline results of the Phase 2b AP (CARPO) trial.
- Tranche B Warrants: Exercise price $7.15; expire on December 31, 2026, or 30 days after topline results of the planned Phase 2 AKI trial.
- Financial Statement Review: The review of financial statements for the year ended December 31, 2023, is ongoing; preliminary figures are unaudited and subject to change.
- Registration Rights Penalties: If the Company fails to file or maintain the effectiveness of the registration statement as agreed, it must pay liquidated damages of 1.0% of the purchase price per month to holders.
- Clinical Trial Risks: Outcomes may differ from expectations; regulatory approval is not guaranteed.
- Market Risks: Fluctuations in global financial markets and the Company's ability to execute its strategy.
Investor Verification Checklist
- Verify Closing Dates: Confirm the actual closing dates of the initial and second closings (expected Jan 23 and Feb 5, 2024).
- Confirm Final Proceeds: Monitor the actual gross proceeds received versus the anticipated $20.4 million upfront.
- Registration Statement Status: Track the filing and effectiveness of the registration statement for the resale of shares to ensure no liquidated damages are triggered.
- Audited Financials: Await the audited financial statements for the year ended December 31, 2023, to confirm the $11.2 million cash position.
- Warrant Exercise Conditions: Monitor the timeline for the Phase 2b AP and Phase 2 AKI trial topline results, which dictate warrant expiration dates.